Stay updated on Expanded Access of Lifileucel in Melanoma: Clinical Trial
Sign up to get notified when there's something new on the Expanded Access of Lifileucel in Melanoma: Clinical Trial page.

Latest updates to the Expanded Access of Lifileucel in Melanoma: Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page has been updated to reflect an increase in study locations from 11 to 14, with specific new locations added in Arizona, Ohio, and Washington, including details about the institutions available at each site.SummaryDifference6%
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe webpage now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check47 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check62 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check69 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference0.4%
- Check91 days agoChange DetectedThe study has expanded to include 11 locations across Kansas, Kentucky, Missouri, and South Dakota, with the latest update posted on December 18, 2024.SummaryDifference6%
Stay in the know with updates to Expanded Access of Lifileucel in Melanoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Expanded Access of Lifileucel in Melanoma: Clinical Trial page.